Publication for MS4A1 and CR2

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MS4A1	membrane spanning 4-domains A1	931			[link]
hsa	CR2	complement C3d receptor 2	1380

Pubmed ID	Priority	Text
18366248	0.96	CD20 mAb binding on freshly isolated B cells using flow cytometry with anti-CD20 mAbs and a PE-conjugated anti-CD21 mAb.
	0.78	CD20 mAb B1 resulted in a decreased CD20/CD21 MFI ratio for three out of five patients (unpublished data).
	0.67	CD20 mAb binding intensity (MFI) was correlated to CD21 mAb binding intensity by calculating the ratio of CD20/CD21 MFI.
	0.60	CD20/CD21 mAb staining was calculated and served as a relative measure for CD20 expression.
24187614	0.96	CD20+CD5+CD10+/-CD21+/-CD23+/-IgM+IgD+/- and CD38+, but once they have evolved to type 2 (BT2), they become CD20+CD5+/-CD21++CD23+/-IgM++IgD++ and CD38+/-.
30116248	0.95	CD21, CD40, LYN, MS4A1, ORAI1, PLCG2, PTPRC, and STIM1 deficiency attractors.
	0.87	CD21, CD40, LYN, MS4A1, and PTPRC (Figure 4).
	0.82	CD21, CD40, CD81, IKKB, KRAS, LYN, MALT1, MS4A1, NEMO, NFKB1, NFKBIA, ORAI1, PI3K, PLCG2, PTPRC, STIM1, and WIPF1 deficiencies.
	0.79	CD21, CD40, LYN, MS4A1, and PTPRC PID attractors.
	0.69	CD21, CD40, CD81, IKKB, LYN, MALT1, MS4A1, NEMO, NFKB1, NFKBIA, ORAI1, PI3K, PLCG2, STIM1, and WIPF1 and knockin perturbation of CARD11 gain-of-function, KRAS, NFKBIA, and PI3K) attractors.
21450903	0.95	B1 cells (fractionated into CD21+ (B121+) and CD21- (B121-) subsets).
	0.54	CD21 identified two clear splenic B1 subsets, and D6active MZ B cells amongst IgMhiCD23loCD5- cells (Figure 5C).
21304587	0.94	CD20+ B cells were further analyzed based on their CD21 and CD27 surface molecule expression.
	0.91	CD20+ B cells based on CD27 and CD21 surface expression and their functional characteristics (e.g. IgG production).
	0.90	CD21+CD27+CD20+ B cells are memory B cells that can be activated and induced to proliferate and differentiate into antibody secreting cells via polyclonal activation without T cell help.
	0.81	CD20 in all B cell subsets, and upregulation of CD138 expression in DP CD21+CD27+ B cells.
29717110	0.94	MS4A1 (CD20), ITGAX (CD11c), TBX21 (T-bet), CR2 (CD21), FCER2 (CD23), FCGR2B (CD32B), CD24, CD27, CD38, CD40 and IL-21R (Fig. 5c, Supplementary Note 1).
28133792	0.93	CD20, as well as IgM and IgD. Bone marrow B-cell emigrants maintain expression of the pre-B cell surface marker CD10, while expressing low levels of the complement receptor CD21.
28567040	0.93	CD20+ B cells (Figure 3C) and large CD21+ FDC networks (Figure 3G), indicating that despite the suppressive environment, activated B cells were still able to induce the differentiation of tumor-associated stromal cells into FDC.
27641977	0.92	CD21 displayed the strongest activity in blocking HCV binding to B cells, followed by anti-CD20, anti-CD35, and anti-CD81.
	0.86	CD20 is one of major B cell markers, CD21 is also known as complement receptor 2, CD32 is receptor for Fc fragment of immunoglobulin G, CD35 is complement receptor 1, and CD55 is membrane-bound decay-accelerating factor for convertases of complement system.
28667164	0.92	CD20+/HLADR+ /CD21-/CD27+) and resting (CD3-/CD20+/HLADR+/CD21+ /CD27+) memory B cell numbers remained constant until day 70.
28735813	0.92	CD20+ CD21Lo CD27- CD11cHi.
25517315	0.90	CD20, CD21 and CD22 levels and modulates various surface antigens, it does not substantially influence other targets for mAbs-mediated therapy, such as CD38, CD52 and CD19 (Fig. S6).
25088080	0.87	B-1 cells express CD11b, higher levels of IgM (sIgM), and low levels of secreted IgD (sIgD), CD21, CD23, and CD45R (B220).
23826242	0.86	CD20 markers, so we do not know what fraction of the CD19+IgD-CD27-CD21- MBC observed in this study are the "exhausted" atypical MBC (CD19+CD10-CD27-CD21-) described in patients with high level HIV viremia and in malaria-exposed individuals from other populations.
27844106	0.86	CD20 and CD22, several other biomarkers have been investigated as targets for RIT in lymphoma, including the human leukocyte antigen DR (HLA-DR), CD21, and CD37.
29530739	0.86	CD20+), Follicular B cells(CD23+), Plasma cells (CD138), Follicular Dendritic Cells (CD21+) and macrophage/monocytes (CD68+).
30723574	0.86	CD21-) and activated (CD86+) B cells were evaluated in CD19+/CD20+/CD45+ B cells.
28063478	0.85	CD20, CD21, CD22, CD27, CD40, CD45RA, CD79A, CD79B, and RAG-2 in the fetal liver, bone marrow, and spleen was measured at 90-120DG.
22477523	0.79	CD20, CD21 and CD81), each of which forms complexes with the B cell antigen receptor, appear to lower the threshold for B cell activation (Fig. 1).
	0.79	CD20 and CD81, CD21, also known as CR2 due to its role as a complement receptor, focuses antigen activation on the BCR.
23455507	0.63	B-1 cells, primate CD11b+ B cells expressed higher FSC, IgM, and CD19, and lower levels of CD21 relative to CD11b- B cells (Fig. 1C).
23565504	0.60	CD20, CD21, CD22, and CD30 (see Table 1 for an overview).
31877281	0.56	CD20+ cells and CD3+ cells segregated into anatomically distinct but adjacent zones, with a CD21+ follicular dendritic cell (FDC) network, CD23+ cells and BCL6 staining in the B cell zone (Figs. 1 and 2).